Pro Con debates in clinical medicine Infection prevention and control in cystic fibrosis: one size fits all? The argument against by Smyth, A.R. et al.
Journal Pre-proofs
Review
Pro Con debates in clinical medicine Infection prevention and control in cystic
fibrosis: one size fits all? The argument against
A.R. Smyth, S. Smith, N.J. Robotham
PII: S1526-0542(19)30066-1
DOI: https://doi.org/10.1016/j.prrv.2019.08.001
Reference: YPRRV 1338
To appear in: Paediatric Respiratory Reviews
Received Date: 7 August 2019
Accepted Date: 9 August 2019
Please cite this article as: A.R. Smyth, S. Smith, N.J. Robotham, Pro Con debates in clinical medicine Infection
prevention and control in cystic fibrosis: one size fits all? The argument against, Paediatric Respiratory Reviews
(2019), doi: https://doi.org/10.1016/j.prrv.2019.08.001
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover
page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will
undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing
this version to give early visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2019 Elsevier Ltd. All rights reserved.
 1 
Pro Con debates in clinical medicine 
 
 
Infection prevention and control in cystic fibrosis: one size fits all? The argument against. 
 
 
Smyth AR1,2,3, Smith S1,2, Robotham NJ1,2 
 
 
1. School of Medicine, University of Nottingham, Nottingham UK. 
2. Nottingham Evidence Based Child Health Group, School of Medicine, University of Nottingham, 
Nottingham, UK. 
3. Nottingham Children’s Hospital, Nottingham, UK 
 
 
Corresponding author: 
Alan R Smyth, Professor of Child Health, School of Medicine, University of Nottingham, 
Nottingham UK. 
Email:  
 
Keywords: 
Infection prevention, evidence, practice, cystic fibrosis 
 
 
Educational aims: 
The reader will come to: 
 Appreciate that infection prevention measures in cystic fibrosis are based on theoretical 
benefit more than proven efficacy. 
 Understand that to be successful, infection control measures need to be simple, universally 
applied and acceptable. 
 
Future directions for research: 
 Provide evidence for or against simple measures such as masks, gowns and gloves as the 
centrepiece of infection prevention. 
 Justify the role of highly expensive frequent air cycling in clinical rooms . 
 
 
 
 
Abstract 
As awareness of the risks of cross infection has increased, infection prevention and control 
measures have become more draconian. Infection control measures can have a profound effect of 
the organisation and delivery of CF services and on the lives of people with CF outside the 
hospital. However, the consequences of inadequate infection control measures may be the 
permanent acquisition of a chronic infection which is virtually untreatable. Recommendations for 
infection prevention and control therefore must protect patients but should also be evidence-based 
and proportionate. This article will review the literature, juxtaposing evidence and popular practice.    
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The last half century has seen a dramatic improvement in the life expectancy and quality of life for 
people with cystic fibrosis (CF).1 Much of the early improvement in these outcomes has been 
attributed to the frequent use of 14 day courses of intravenous antibiotics, particularly for those 
patients who have chronic pulmonary infection with Pseudomonas aeruginosa.2 Furthermore, long 
term antibiotic regimens are used in CF such as oral azithromycin and inhaled antibiotics (e.g. 
colistimethate sodium, tobramycin and aztreonam). Each of these approaches will contribute to 
the selection of resistant organisms in the CF airway. Patients with CF may therefore develop 
chronic pulmonary infection with multi-drug resistant organisms including: P. aeruginosa; 
methicillin resistant Staphylococcus aureus (MRSA); Burkholderia cepacia complex and non-
tuberculous mycobacteria, particularly Mycobacterium abscessus.3 
 
Since these infections were first described in CF, there has been concern that multi-drug resistant 
infection can be acquired by person to person spread between CF patients or from an 
environmental source (either in the CF centre or the home). Person to person spread has been 
proposed for multi-drug resistant P. aeruginosa,4 MRSA,5 B. cepacia complex6 and M. 
abscessus.7 Acquisition of both P. aeruginosa8 and MRSA5 from the hospital environment has 
been suggested. P. aeruginosa is present in the homes of CF patients with a new pulmonary 
infection but it has not been established whether the patient contaminates their environment or 
vice versa.9 Uncertainty about the risks of acquiring infection either from other patients or from the 
environment has given rise to pervasive anxiety in the CF community.10 In one survey, parents 
reported using a mean of 11 “hygienic measures” in the home, including ensuring their child had a 
different toothbrush for morning and evening and removing all pot plants from the house.11  
 
As awareness of the risks of cross infection has increased, infection prevention and control 
measures have become more draconian. Following reports of the transmission of Burkholderia 
cepacia complex by social contact, infection control guidelines were published advising against 
any social contact between people with CF and avoiding activities such as CF camps.12 The first 
edition of the US CF Foundation consensus document on infection control13 stated that: “No 
recommendation can be made for the routine wearing of masks by CF patients…” The most recent 
edition of the same guideline14 states that: “All people with CF, regardless of respiratory tract 
culture results, should wear a surgical…mask when in a healthcare setting…” Infection control 
measures can have a profound effect of the organisation and delivery of CF services and on the 
lives of people with CF outside the hospital. However, the consequences of inadequate infection 
control measures may be the permanent acquisition of a chronic infection which is virtually 
untreatable. Recommendations for infection prevention and control therefore must protect patients 
but should also be evidence-based and proportionate.  
 
So how robust is the evidence? That depends on how high we set the bar. Conventional clinical 
trials are designed to show a difference (improvement) in the group mean with an intervention. 
With cross infection, we are in pursuit of zero infection and so an improvement in the group mean 
may not be enough. A recent systematic review found only 2 randomised controlled trials of 
infection prevention and control measures in CF – the majority of studies being a “before and 
after” design.15  
 
 Segregation. When patients attend their CF centre, it is no longer proposed that they are 
cohorted together with other patients who have the same organism but rather individual 
segregation is recommended. These changes have been driven by the observation that an 
epidemic strain of P. aeruginosa can cross-infect patients with less pathogenic strains16 and 
by the unquantifiable risk of a new transmissible pathogen appearing within a cohort who 
are mixing freely. Only one study (before and after) has evaluated individual segregation of 
CF patients and this found no significant difference in acquisition of P. aeruginosa after 
segregation was introduced.17 A post hoc subgroup analysis of these data suggested that 
acquisition of P. aeruginosa was reduced in children.  
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 Hand hygiene is practiced universally in health care settings and is acceptable to patients 
and staff. One before and after study has examined the efficacy of hand hygiene in CF but 
did not demonstrate a reduced risk of transmission with hand hygiene measures.18  
 Gowns and gloves. A systematic review, looked at 23 studies of glove use in health 
workers and found that, although gloving can reduce acquisition of microorganisms on the 
hands, inappropriate glove use is frequent and can increase the risk of transmission of 
infection by health workers.19 An observational study on a medical ward and intensive care 
unit documented that frequently gloves were neither discarded nor hand hygiene performed 
after patient contact.20 A study in 4 US hospitals found that skin contamination of the health 
worker occurred during gown and glove removal in 46% of cases.21 Current CF infection 
control guidelines recommend that gowns and gloves are worn for all patient contact.14  
 Face masks. Perhaps one of the most contentious issues is the question of whether face 
masks should be worn by all CF patients when attending the CF centre. A randomised 
controlled trial of face mask use found that air contamination during CF clinic visits was 
infrequent and was not reduced by the use of masks.18 In contrast, studies of air 
contamination in CF adults using a “cough rig” have shown that face masks reduce the 
generation of P. aeruginosa aerosols22 and that the density of organisms is reduced for 
wear periods of up to 40 minutes.23   
 High-efficiency particulate air (HEPA) filters and air changes. Performing spirometry 
has been shown to increase room air contamination24 and it is recommended that a HEPA 
filter is used in the spirometry room (equivalent to 12 air changes per hour) or else 30 
minutes should elapse before the room is used by the next patient.14 However, differences 
in the number of air changes per hour have not been shown to affect air contamination.24  
 
None of these recommendations will be effective if they are not implemented consistently by 
patients and staff. A recent survey of paediatric CF centres in Ireland showed that only one centre 
adhered to the recommendation on gowns and gloves and no centres followed the 
recommendation on use of face masks or room ventillation.25 There is some evidence which 
suggests that infection control measures can compromise patient care.26  
 
So does infection prevention and control allow room for pragmatism? Hand hygiene and individual 
segregation should be practiced in every CF centre. However HEPA filtration may work best when 
it is part of the design of new-build CF facilities. In the meantime, many centres will have to opt for 
leaving spirometry rooms vacant and ventilated for 30 minutes after use. Glove use may add little 
to infection prevention through simple hand hygiene. Indeed gloves may give false reassurance 
and may lead to appropriate hand hygiene being omitted after patient contact. Face masks remain 
controversial and their efficacy in children has not yet been demonstrated. Some paediatric 
centres may await further evidence before deciding on the use of face masks. There is little 
evidence on how to reduce environmental acquisition in the home and CF centres should restrict 
their advice to measures which are evidence-based and readily implemented. Careful pragmatic 
implementation of infection control should aim to protect patients whilst avoiding stigmatisation 
and anxiety. 
 
REFERENCES 
 
1. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 
1947-2003. Eur Respir J. 2007;29(3):522-526. 
2. Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the Danish center-treated 
cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol. 1996;21(3):153-
158. 
3. UK Cystic Fibrosis Trust. UK CF Registry. Annual Data Report 2017. London: Cystic 
Fibrosis Trust; 2018. 
4. Cheng K, Smyth RL, Govan JRW, et al. Spread of β-lactam-resistant Pseudomonas 
aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348(9028):639-642. 
 4 
5. Harik NS, Com G, Tang X, Melguizo Castro M, Stemper ME, Carroll JL. Clinical 
characteristics and epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in 
children with cystic fibrosis from a center with a high MRSA prevalence. Am J Infect 
Control. 2016;44(4):409-415. 
6. Govan JR, Brown PH, Maddison J, et al. Evidence for transmission of Pseudomonas 
cepacia by social contact in cystic fibrosis. Lancet. 1993;342(8862):15-19. 
7. Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-
transmissible multidrug-resistant nontuberculous mycobacterium. Science. 
2016;354(6313):751-757. 
8. Smyth A, Heaf D, Corkill J, Hart T, Sisson P, Freeman R. Transmission of Pseudomonas-
Cepacia by Social Contact in Cystic-Fibrosis. Lancet. 1993;342(8868):434-435. 
9. Schelstraete P, Van Daele S, De Boeck K, et al. Pseudomonas aeruginosa in the home 
environment of newly infected cystic fibrosis patients. Eur Respir J. 2008;31(4):822-829. 
10. Palser SC, Rayner OC, Leighton PA, Smyth AR. Perception of first respiratory infection with 
Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online 
qualitative study. BMJ Open. 2016;6(12):10.1136/bmjopen-2016-012303. 
11. Ullrich G, Wiedau S, Schulz W, Steinkamp G. Parental knowledge and behaviour to prevent 
environmental P. aeruginosa acquisition in their children with CF. J Cys Fibros. 
2008;7(3):231-237. 
12. UK Cystic Fibrosis Trust Infection Control Group. Pseudomonas aeruginosa infection in 
people with cystic fibrosis. Suggestions for prevention and infection control. Bromley: UK 
CF Trust   2004. 
13. Saiman L, Siegel J, Cystic Fibrosis Foundation Consensus Conference on Infection Control 
P, Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: 
Microbiology, important pathogens, and infection control practices to prevent patient-to-
patient transmission. [Review] [395 refs]. A J Infect Control. 2003;31(3 Suppl):S1-62. 
14. Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic 
fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35 Suppl 1:S1-S67. 
15. Rowbotham NJ, Palser SC, Smith SJ, Smyth AR. Infection prevention and control in cystic 
fibrosis: a systematic review of interventions. Expert Rev Respir Med. 2019:1-10. 
16. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection 
with a transmissable strain of  Pseudomonas aeruginosa  in adults with cystic fibrosis 
chronically colonised by  P aeruginosa Lancet. 2001;358:558-560. 
17. van Mansfeld R, de Vrankrijker A, Brimicombe R, et al. The Effect of Strict Segregation on 
Pseudomonas aeruginosa in Cystic Fibrosis Patients. PLoS One. 2016;11(6):e0157189. 
18. Zuckerman JB, Zuaro DE, Prato BS, et al. Bacterial contamination of cystic fibrosis clinics. 
J Cyst Fibros. 2009;8(3):186-192. 
19. Picheansanthian W, Chotibang J. Glove utilization in the prevention of cross transmission: a 
systematic review. JBI database of systematic reviews and implementation reports. 
2015;13(4):188-230. 
20. Girou E, Chai SH, Oppein F, et al. Misuse of gloves: the foundation for poor compliance 
with hand hygiene and potential for microbial transmission? J Hosp Infect. 2004;57(2):162-
169. 
21. Tomas ME, Kundrapu S, Thota P, et al. Contamination of Health Care Personnel During 
Removal of Personal Protective Equipment. JAMA internal medicine. 2015;175(12):1904-
1910. 
22. Wood ME, Stockwell RE, Johnson GR, et al. Face Masks and Cough Etiquette Reduce the 
Cough Aerosol Concentration of Pseudomonas aeruginosa in People with Cystic Fibrosis. 
Am J Respir Crit Care Med. 2018;197(3):348-355. 
23. Stockwell RE, Wood ME, He C, et al. Face Masks Reduce the Release of Pseudomonas 
aeruginosa Cough Aerosols When Worn for Clinically Relevant Periods. Am J Respir Crit 
Care Med. 2018;198(10):1339-1342. 
 5 
24. Zuckerman JB, Clock SA, Prato BS, et al. Air Contamination with Bacteria in Cystic Fibrosis 
Clinics: Implications for Prevention Strategies. Am J Respir Crit Care Med. 
2015;191(5):598-601. 
25. Breen C, Finn D, Greally P, O’Connell G, Elnazir B. A national paediatric survey of infection 
control measures in cystic fibrosis. Ir J Med Sci. 2015;184(Suppl 7):S278–S279. 
26. Saint S, Higgins LA, Nallamothu BK, Chenoweth C. Do physicians examine patients in 
contact isolation less frequently? A brief report. Am J Infect Control. 2003;31(6):354-356. 
 
